Results 81 to 90 of about 5,279 (205)
VIEW, Volume 7, Issue 4, August 2026.This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu +10 more
wiley +1 more source
Fact sheet for Paxlovid. Marshallese
, 2021 Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 MARSHALLESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and
core
ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants
Journal of Medical Virology, Volume 98, Issue 7, July 2026.ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández +5 more
wiley +1 more source
Fact sheet for Paxlovid. Chuukese
, 2021 Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 CHUUKESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Computational prediction of interactions between Paxlovid and prescription drugs
, 2023 Pfizer’s Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients
Lee, Sang Yup +7 more
core +1 more source
The pivotal role of β‐lactone stereochemistry in the development of SARS‐CoV‐2 Mpro inhibitors
Protein Science, Volume 35, Issue 7, July 2026.Abstract From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides ...
Katarzyna Świderek, Vicent Moliner
wiley +1 more source
Fact sheet for Paxlovid. Spanish
, 2021 Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 SPANISH"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may
core
Association between Paxlovid and mortality in severe COVID-19 patients: a retrospective cohort study
Journal of Infection in Developing CountriesIntroduction: With limited research on the clinical effectiveness of Paxlovid for hospitalized patients with severe COVID-19, this study aims to assess its impact on clinical outcomes, providing essential insights for patient care.
Bin Liu +9 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 7, July 2026.ABSTRACT COVID‐19 continues to be a threat to global health and a burden on healthcare systems. There is an ongoing need for COVID‐19 antiviral therapies that are safe and effective across broad patient populations. Ibuzatrelvir is a potent, selective inhibitor of the SARS‐CoV‐2 main protease and demonstrated favorable properties for clinical ...
Ravi Shankar P. Singh +10 more
wiley +1 more source